Reports started with ABCB1 and ABCG2 overexpression in Philadelphia chromosome-positive chronic myeloid leukemia cells as a consequence of imatinib selection [38]. The gene discussed is ABCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.